MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Alcon Inc

Suletud

SektorTervishoid

92.53 -2.44

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

92.11

Max

94.9

Põhinäitajad

By Trading Economics

Sissetulek

21M

284M

Müük

48M

2.5B

P/E

Sektori keskmine

46.307

63.778

Aktsiakasum

0.72

Dividenditootlus

0.28

Kasumimarginaal

11.351

Töötajad

25,599

EBITDA

56M

397M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+13.2% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.28%

2.39%

Järgmine tulemuste avaldamine

13. mai 2025

Turustatistika

By TradingEconomics

Turukapital

5.9B

47B

Eelmine avamishind

94.97

Eelmine sulgemishind

92.53

Uudiste sentiment

By Acuity

50%

50%

173 / 386 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

Alcon Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

26. märts 2025, 21:22 UTC

Omandamised, ülevõtmised, äriostud

Alcon Buys Majority Stake in Aurion to Advance Eye Disease Treatment

24. märts 2025, 12:36 UTC

Omandamised, ülevõtmised, äriostud

Alcon to Buy Lensar in Deal Worth Up to $430 Million

12. nov 2024, 18:48 UTC

Tulu
Suurimad hinnamuutused turgudel

Alcon Posts Higher 3Q Sales and Profit, Lowers 2024 Sales View

26. märts 2025, 21:55 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Alcon Deal for Aurion Follows 2022 Investment, 2024 Lawsuit -- Market Talk

26. märts 2025, 20:33 UTC

Omandamised, ülevõtmised, äriostud

Aurion Board Appoints Arnaud Lacoste as CEO of Aurion

26. märts 2025, 20:32 UTC

Omandamised, ülevõtmised, äriostud

Alcon: Aurion Will Operate as a Separate Company With Full Support From Alcon to Advance Its Clinical-Stage Allogeneic Cell Therapy Asset

26. märts 2025, 20:32 UTC

Omandamised, ülevõtmised, äriostud

Leverages Alcon's Global Scale With Aurion's Cell Therapy Expertise to Accelerate U.S. Phase 3 Development in Fall of 2025 >ALC.EB

26. märts 2025, 20:31 UTC

Omandamised, ülevõtmised, äriostud

Alcon Acquires Interest in Aurion to Advance Innovative Cell Therapy for Corneal Endothelial Disease >ALC.EB

26. märts 2025, 20:31 UTC

Omandamised, ülevõtmised, äriostud

Alcon Inc. Unit Alcon Research Previously Sued Aurion to Prevent It From Going Public

26. märts 2025, 20:31 UTC

Omandamised, ülevõtmised, äriostud

Alcon Acquires Majority Interest in Aurion Biotech >ALC.EB

26. märts 2025, 20:30 UTC

Omandamised, ülevõtmised, äriostud

Alcon Acquires Majority Interest in Aurion Biotech

24. märts 2025, 12:21 UTC

Omandamised, ülevõtmised, äriostud

Alcon to Buy Lensar in Deal Worth Up to $430M

24. märts 2025, 12:05 UTC

Omandamised, ülevõtmised, äriostud

Alcon: Transaction Is Anticipated to Close in Mid-To-Late 2025 >ALC

24. märts 2025, 12:05 UTC

Omandamised, ülevõtmised, äriostud

Alcon: Transaction Represents a Total Consideration of Up to About $430M >ALC

24. märts 2025, 12:04 UTC

Omandamised, ülevõtmised, äriostud

Alcon: Additional Non-Tradeable Contingent Value Right Offering Up to $2.75 Per Shr in Cash, Conditioned on Achievement of 614,000 Cumulative Procedures With LENSAR's Products Between Jan 1, 2026, and Dec 31, 2027 >ALC

24. märts 2025, 12:04 UTC

Omandamised, ülevõtmised, äriostud

Alcon Will Purchase All Outstanding Shrs of LENSAR for $14.00 Per Shr in Cash >ALC

24. märts 2025, 12:03 UTC

Omandamised, ülevõtmised, äriostud

Alcon: Acquisition Includes ALLY Robotic Cataract Laser Treatment System, LENSAR's Proprietary Streamline Software Technology and LENSAR Legacy Laser System >ALC

24. märts 2025, 12:03 UTC

Omandamised, ülevõtmised, äriostud

Alcon Agrees to Acquire LENSAR >ALC

24. märts 2025, 12:00 UTC

Omandamised, ülevõtmised, äriostud

Alcon Agrees To Acquire LENSAR, Inc. >ALC LNSR

25. veebr 2025, 21:33 UTC

Tulu

Alcon Sees 2025 Adj EPS $3.15-Adj EPS $3.25 >ALC.EB

25. veebr 2025, 21:33 UTC

Tulu

Alcon Sees 2025 Sales $10.2B-$10.4B >ALC.EB

25. veebr 2025, 21:32 UTC

Tulu

Alcon: Board Authorized the Repurchase of Up to $750M of the Company's Common Shrs >ALC.EB

25. veebr 2025, 21:31 UTC

Tulu

Alcon 4Q EPS 57c >ALC.EB

25. veebr 2025, 21:31 UTC

Tulu

Alcon 4Q Rev $2.5B >ALC.EB

17. dets 2024, 15:05 UTC

Market Talk

Alcon's Late-Stage Pipeline Set To Drive Revenue Growth Next Year -- Market Talk

12. nov 2024, 17:38 UTC

Tulu

Alcon Narrows 2024 View To Adj EPS $3.00-Adj EPS $3.05 >ALC

12. nov 2024, 17:38 UTC

Tulu

Alcon Had Seen 2024 Sales $9.9B-$10.1B >ALC

12. nov 2024, 17:37 UTC

Tulu

Alcon Cuts 2024 View To Sales $9.8B-$9.9B >ALC

12. nov 2024, 17:36 UTC

Tulu

Alcon 3Q Core Operating Margin 20.6% >ALC

12. nov 2024, 17:36 UTC

Tulu

Alcon 3Q Sales $2.43B >ALC

Võrdlus sarnastega

Hinnamuutus

Alcon Inc Prognoos

Hinnasiht

By TipRanks

13.2% tõus

12 kuu keskmine prognoos

Keskmine 107.46 USD  13.2%

Kõrge 120 USD

Madal 90 USD

Põhineb 20 Wall Streeti analüütiku instrumendi Alcon Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

20 ratings

18

Osta

2

Hoia

0

Müü

Tehniline skoor

By Trading Central

90.91 / 94.93Toetus ja vastupanu

Lühikene perspektiiv

Strong Bullish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Bullish Evidence

Sentiment

By Acuity

173 / 386 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Alcon Inc

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, ARGOS biometer, LuxOR surgical ophthalmic microscope, SMARTCATARACT health platform, NGENUITY 3D visualization system, Verion reference unit and Verion digital marker, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantable products, including AcrySof IQ products, such as monofocal IOLs and advanced technology IOLs for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.